<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05018182</url>
  </required_header>
  <id_info>
    <org_study_id>2021-010</org_study_id>
    <nct_id>NCT05018182</nct_id>
  </id_info>
  <brief_title>FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer</brief_title>
  <official_title>To Observe the Pathological Remission Rate and Safety of FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer With a Single-arm, Open, Prospective Phase II Exploratory Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main cause of recurrence after surgical treatment of colorectal cancer is distant&#xD;
      metastasis. Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of&#xD;
      chemotherapy. Preoperative chemotherapy may eradicate microscopic metastatic cancer cells&#xD;
      earlier than adjuvant chemotherapy, reduce cancer cell spillage during surgery, and lessen&#xD;
      the invasiveness of surgical resection. The FOLFOXIRI regimen has been shown to have a high&#xD;
      objective efficiency in advanced colorectal cancer. This phase II trial is to explore the&#xD;
      pathological remission rate and safety of stage II/III locally advanced colon cancer with&#xD;
      high risk of recurrence to FOLFOXIRI regimen of neoadjuvant chemotherapy alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2021</start_date>
  <completion_date type="Anticipated">August 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological response</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>The rate of Tumor Regression Grade 0-1 in the resected tumour tissue</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Rate of patients with partial or complete response according to modified RECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic Complete Response (PCR)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Rate of pathological complete response in the resected tumour tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Resection rate, defined as patients with microscopically complete (R0) resection (ITT- population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Progression free survival (Medium, Kaplan-Meier-estimation, ITT- population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival Metastasis-free survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>distant Distant metastasis-free survival (Medium, Kaplan-Meier-estimation, ITT- population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Overall survival (Kaplan-Meier-estimation, ITT- population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and Compliance to study treatment</measure>
    <time_frame>up to 1 years</time_frame>
    <description>Toxicity according to NCI-CTC criteria v. 4.0 Perioperative toxicity according to Clavien</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular markers</measure>
    <time_frame>up to 1 years</time_frame>
    <description>Evaluation of molecular predictive markers for response and toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life to study treatment</measure>
    <time_frame>up to 1 years</time_frame>
    <description>scores of Quality of Life Questionare-Core 30 of the European Organization for Research and Treatment of Cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with 30-day post-operative mortality</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>High-risk Locally Advanced Colorectal Cancer</condition>
  <condition>Neoadjuvant Chemotherapy</condition>
  <condition>FOLFOXIRI Regimen</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles of neoadjuvant chemotherapy with FOLFOXIRI + operation + 5 cycles of adjuvant chemotherapy with XELOX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 85 mg/m² Q2w(2 h) before surgery rection and 130 mg/m² Q3w (2 h) after surgery</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 150 mg/m² ivgtt(1.5 h) Q2w before surgery rection</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <other_name>Campto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <description>Folinic acid 400 mg/m² ivgtt(2 h) Q2w before surgery rection</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <other_name>Leukovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5FU</intervention_name>
    <description>5-FU 2800 mg/m² civ(46 h) Q2w before surgery rection</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000mg/m² d1-14 po Q3w after surgery rection</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-75 years old; Sex: Male or female;&#xD;
&#xD;
          -  WHO performance status of 0, 1 or 2&#xD;
&#xD;
          -  Histologically proven colorectal carcinoma (defined as cancer that is located &gt;10 cm&#xD;
             from the anal verge by endoscopy)&#xD;
&#xD;
          -  Unequivocal radiological evidence of locally advanced cancer based on thin slice&#xD;
             spiral CT [defined as T4a/b or (and) N2 / fused lymph nodes or (and) positive&#xD;
             extramural vascular invasion (EMVI +) or (and) circumferential resection margin (CRM)&#xD;
             ≤ 2mm].&#xD;
&#xD;
          -  No distant metastases (distant organ or (and) distant lymph node metastases) assessed&#xD;
             by CT scan or other radiographic examination.&#xD;
&#xD;
          -  For patients with T4b, R0 resection was expected to be achieved, including the&#xD;
             necessary combined organ resection，by MDT discussion.&#xD;
&#xD;
          -  No history of 5-Fu and platinum drug allergy.&#xD;
&#xD;
          -  Adequate bone marrow function: Hb&gt;9g/dl; PLT &gt;100 x 10^9/l; WBC &gt;3.5 x 10^9/l and ANC&#xD;
             ≥1.5x10^9/l.&#xD;
&#xD;
          -  Adequate hepatobiliary function: ASAT (aspartate aminotransferase) and ALAT (alanine&#xD;
             aminotransferase) of 2.5 x ULN (upper limits of normal) or less, Alkaline phosphatase&#xD;
             of 2.5 x ULN or less, total bilirubin 1.5 x upper normal level or less.&#xD;
&#xD;
          -  Adequate renal biochemistry: GFR &gt;50 ml/min calculated by the Wright or Cockroft&#xD;
             formula or EDTA clearance &gt;70 ml/min.&#xD;
&#xD;
          -  For female and of childbearing potential, patient must have a negative pregnancy test&#xD;
             ≤72hours prior to initiating study treatment and agree to avoid pregnancy during and&#xD;
             for 6 months after study treatment. For male with a partner of childbearing potential,&#xD;
             patient must agree to use adequate, medically approved, contraceptive precautions&#xD;
             during and for 90 days after the last dose of study treatment&#xD;
&#xD;
          -  Patient able and willing to provide written informed consent for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with lynch syndrome&#xD;
&#xD;
          -  Rectal cancer located 10 cm or less from the anal verge.&#xD;
&#xD;
          -  Any patient for whom radiotherapy is advised by the MDT.&#xD;
&#xD;
          -  Patient with evidence of distant metastases or peritoneal nodules (M1).&#xD;
&#xD;
          -  Severe intestinal complications on initial clinical or imaging assessment:&#xD;
             perforation, obstruction, uncontrollable bleeding.&#xD;
&#xD;
          -  Another serious medical condition judged to compromise ability to tolerate neoadjuvant&#xD;
             therapy and/or surgery.&#xD;
&#xD;
          -  Pre-existing or concurrent other malignancies (including concurrent colon cancer),&#xD;
             except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Patients with severe cardiovascular disease and diabetes mellitus that cannot be&#xD;
             easily controlled.&#xD;
&#xD;
          -  Persons with mental disorders.&#xD;
&#xD;
          -  Patients with severe infections.&#xD;
&#xD;
          -  Patients on thrombolytic/anticoagulant therapy, bleeding quality or coagulation&#xD;
             disorders; or aneurysms, strokes, transient ischemic attacks, arteriovenous&#xD;
             malformations in the past year.&#xD;
&#xD;
          -  Previous history of renal disease with urine protein on urinalysis or clinically&#xD;
             significant renal function abnormalities.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weibing Leng, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sichuan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meng Qiu, Ph.D</last_name>
    <phone>+8602885423203</phone>
    <email>qiumeng@wchscu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weibing Leng, Ph.D</last_name>
    <phone>+8602885423203</phone>
    <email>s103470@stu.scu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sichuan University West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weibing Leng</last_name>
      <phone>18980601776</phone>
      <email>s103470@stu.scu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Meng Qiu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

